The stock of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) hit a new 52-week high and has $10.76 target or 109.00% above today’s $5.15 share price. The 7 months bullish chart indicates low risk for the $142.91 million company. The 1-year high was reported on Oct, 6 by Barchart.com. If the $10.76 price target is reached, the company will be worth $155.77 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 9.78 million shares traded hands or 305.81% up from the average. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has risen 58.82% since March 3, 2016 and is uptrending. It has outperformed by 50.48% the S&P500.
Analysts await Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to report earnings on November, 11. They expect $-0.14 earnings per share, up 22.22% or $0.04 from last year’s $-0.18 per share. After $-0.14 actual earnings per share reported by Aurinia Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.”
More recent Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) news were published by: Investorplace.com which released: “Aurinia Pharmaceuticals Inc (AUPH) Makes Comeback on Encouraging Trial Data” on September 30, 2016. Also Seekingalpha.com published the news titled: “Aurinia Pharmaceuticals Share Price Being Unfairly Punished” on August 31, 2016. Seekingalpha.com‘s news article titled: “Aurinia Pharmaceuticals: Large Potential Return” with publication date: May 23, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.